### ğŸ« Critical Care Medicine: Anticholinergic Syndrome

#### âœ… True Statements
1. **Anticholinergic syndrome** can occur after ingestion of drugs with strong anticholinergic properties, including **antihistamines**, **tricyclic antidepressants**, **some antipsychotics**, **anti-Parkinson agents** (e.g., benztropine, bromocriptine, trihexyphenidyl), **atropine**, and **scopolamine**.
2. Clinical features of **anticholinergic toxicity** include **hyperthermia**, **dry skin and mucous membranes**, **tachypnea**, **hypertension**, and **mydriasis**.
3. **Central nervous system manifestations** of anticholinergic syndrome range from **somnolence and coma** to **agitation and seizures**, and **hallucinations** are common.
4. **Sinus tachycardia** is common in anticholinergic toxicity, and **QRS widening** may occur in severe cases.
5. Management of **anticholinergic syndrome** is usually **supportive**, with **benzodiazepines** used for severe agitation, and **physostigmine** may be considered in severe isolated cases.

#### ğŸ’¬ Extra
1. Doxylamine, an over-the-counter antihistamine used as a sleep aid, is a typical cause of anticholinergic syndrome.
5. Physostigmine is reserved for severe, isolated anticholinergic toxicity because it can reverse both peripheral and central manifestations.

#### ğŸ·ï¸ Tags
#CriticalCare #Toxicology #AnticholinergicSyndrome #Antihistamines #Physostigmine #Benzodiazepines

#### ğŸ“š Reference
McCoy CE, Honda R. Anticholinergic toxicity in the emergency department. *J Educ Teach Emerg Med*. 2023;8:S25-47. PMID: 37465041 doi:10.21980/J8D07Z

#### ğŸ†” Question ID
CCMCQ24008

#### ğŸ•’ Last Updated
February 2025

---

#### ğŸ“– Related Text
MKSAP 19: Critical Care Medicine â€” Specific Critical Care Topics, Toxicology, Toxicity of Drugs of Abuse

---

### ğŸ“˜ Related Text Derivations

#### âœ… True Statements
1. Recognition of **clinical toxic syndromes** provides important diagnostic and management clues in drug overdose when history is unreliable.
2. In suspected **opioid overdose**, an early empiric trial of **naloxone** should be given, titrated to adequate **respiration rate**, not to mental status.
3. **Naloxone** has a short half-life, so patients require observation for **recurrent respiratory depression** and may need repeated doses or intravenous infusion.
4. **Flumazenil** use in **benzodiazepine overdose** carries a risk of **life-threatening seizures**, especially in chronic benzodiazepine users.
5. **Benzodiazepines** are the cornerstone of therapy for agitation in **sympathomimetic agent toxicity** (e.g., cocaine, amphetamines).
6. **Î²-Blockers** should be avoided in **sympathomimetic toxicity** because unopposed **Î±-adrenergic activity** can cause severe hypertension.
7. **Hallucinogenic agent overdose** has no antidote and is managed supportively with airway protection, ventilation, and hemodynamic support.

#### ğŸ’¬ Extra
2. Naloxoneâ€™s goal is to restore breathing, not consciousness; overshooting can precipitate acute withdrawal.
4. Flumazenil is generally avoided unless in very select, controlled settings with ventilatory support.
6. This caution applies especially with pure Î²-blockers; labetalol (with Î±-blocking activity) is sometimes used.

#### ğŸ·ï¸ Tags
#Toxicology #Overdose #Naloxone #Flumazenil #SympathomimeticToxicity #Hallucinogens #SupportiveCare

---

#### ğŸ–¼ï¸ Supplemental Figures
<figure>
  <img src="1fad8b26-66f0-4394-9cd7-24d50ff78afc.png" alt="Table: Toxic Syndromes and Their Manifestations" />
  <figcaption><strong>Toxic Syndromes and Their Manifestations</strong></figcaption>
</figure>
<figure>
  <img src="f88ded70-ad65-41bc-8108-8b6e39ffc3de.png" alt="Table: Presentation and Management of Some Drugs of Abuse" />
  <figcaption><strong>Presentation and Management of Some Drugs of Abuse</strong></figcaption>
</figure>

---

#### ğŸ—¾ Supplemental Tables

<!-- Table 1: Toxic Syndromes and Their Manifestations -->
<table>
  <caption><strong>Toxic Syndromes and Their Manifestations</strong></caption>
  <thead>
    <tr>
      <th>Syndrome</th>
      <th>Manifestations</th>
      <th>Representative Drugs</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Sympathomimetic</td>
      <td>
        Tachycardia<br>
        Hypertension<br>
        Diaphoresis<br>
        Agitation<br>
        Seizures<br>
        Mydriasis
      </td>
      <td>
        Cocaine<br>
        Amphetamines<br>
        Ephedrine<br>
        Caffeine
      </td>
    </tr>
    <tr>
      <td>Cholinergic</td>
      <td>
        SLUDGE (Salivation, Lacrimation, increased Urination and Defecation, Gastrointestinal upset, and Emesis)<br>
        Confusion<br>
        Bronchorrhea<br>
        Bradycardia<br>
        Miosis
      </td>
      <td>
        Organophosphates (insecticides, sarin)<br>
        Carbamates<br>
        Physostigmine<br>
        Edrophonium<br>
        Nicotine
      </td>
    </tr>
    <tr>
      <td>Anticholinergic</td>
      <td>
        Hyperthermia<br>
        Dry skin and mucous membranes<br>
        Agitation, delirium<br>
        Tachycardia, tachypnea<br>
        Hypertension<br>
        Mydriasis
      </td>
      <td>
        Antihistamines<br>
        Tricyclic antidepressants<br>
        Anti-Parkinson agents<br>
        Atropine<br>
        Scopolamine
      </td>
    </tr>
    <tr>
      <td>Opioids</td>
      <td>
        Miosis<br>
        Respiratory depression<br>
        Lethargy, confusion<br>
        Hypothermia<br>
        Bradycardia<br>
        Hypotension
      </td>
      <td>
        Morphine, fentanyl, oxycodone, and related drugs<br>
        Heroin
      </td>
    </tr>
  </tbody>
</table>

#### âœ… True Statements (from Table: Toxic Syndromes and Their Manifestations)
1. **Sympathomimetic toxicity** presents with **tachycardia**, **hypertension**, **diaphoresis**, **agitation**, **seizures**, and **mydriasis**; representative drugs include **cocaine**, **amphetamines**, **ephedrine**, and **caffeine**.
2. **Cholinergic toxicity** presents with **SLUDGE symptoms**, **confusion**, **bronchorrhea**, **bradycardia**, and **miosis**; representative exposures include **organophosphates**, **carbamates**, **physostigmine**, **edrophonium**, and **nicotine**.
3. **Anticholinergic toxicity** presents with **hyperthermia**, **dry skin and mucous membranes**, **agitation or delirium**, **tachycardia/tachypnea**, **hypertension**, and **mydriasis**; representative drugs include **antihistamines**, **tricyclic antidepressants**, **antiâ€‘Parkinson agents**, **atropine**, and **scopolamine**.
4. **Opioid toxicity** presents with **miosis**, **respiratory depression**, **lethargy/confusion**, **hypothermia**, **bradycardia**, and **hypotension**; representative drugs include **morphine**, **fentanyl**, **oxycodone**, and **heroin**.

---

<!-- Table 2: Presentation and Management of Some Drugs of Abuse -->
<table>
  <caption><strong>Presentation and Management of Some Drugs of Abuse</strong></caption>
  <thead>
    <tr>
      <th>Drug Class</th>
      <th>Examples</th>
      <th>Examination Findings</th>
      <th>Antidote</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Opioids</td>
      <td>Heroin, oxycodone, fentanyl analogs</td>
      <td>Bradycardia, hypothermia, hypotension, decreased respiration rate, miosis</td>
      <td>Naloxone</td>
    </tr>
    <tr>
      <td>Benzodiazepines</td>
      <td>Lorazepam</td>
      <td>CNS depression, typically normal vital signs and eye examination</td>
      <td>Flumazenil (not generally recommended; reversal of benzodiazepine effect may lead to seizure)</td>
    </tr>
    <tr>
      <td rowspan="5">Sympathomimetics<br><em>All</em></td>
      <td>â€”</td>
      <td>Tachycardia, hypertension, fever, diaphoresis, mydriasis, agitation, seizure, â†‘ creatine kinase, â†‘ liver chemistry studies, â†‘ Cr</td>
      <td>Benzodiazepines are first line for agitation; avoid Î²â€‘blockers for hypertension; haloperidol may worsen hyperthermia</td>
    </tr>
    <tr>
      <td><em>Specific drugs: Cocaine</em></td>
      <td>Myocardial infarction prominent; 30â€‘minute duration</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td><em>Methamphetamine</em></td>
      <td>Violent agitation prominent; hyponatremia; 20â€‘hour duration</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td><em>MDMA (â€œecstasyâ€)</em></td>
      <td>Hyponatremia, serotonin syndrome</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td><em>Bath salts (â€œplant foodâ€)</em></td>
      <td>Hallucinations, violent agitation common; duration up to 48 hours; negative urine drug screen</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td rowspan="5">Hallucinogens</td>
      <td>Dextromethorphan</td>
      <td>Tachycardia, hypertension, agitation, coma</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>Lysergic acid diethylamide (LSD)</td>
      <td>Mild tachycardia; hypertension; rare fever and hemodynamic instability</td>
      <td>Benzodiazepines are first line for agitation</td>
    </tr>
    <tr>
      <td>Phencyclidine (PCP)</td>
      <td>Variable mental status: â†‘ agitation, CNS depression, nystagmus</td>
      <td>â€”</td>
    </tr>
    <tr>
      <td>Synthetic cannabinoids (â€œSpice,â€ â€œKâ€‘2â€)</td>
      <td>Tachycardia; greater agitation than with marijuana; â†‘ Cr; negative urine drug screen</td>
      <td>â€”</td>
    </tr>
  </tbody>
</table>
<p><em>CNS = central nervous system; Cr = creatinine; MDMA = 3â€‘4 methylenedioxymethamphetamine.</em></p>

#### âœ… True Statements (from Table: Presentation and Management of Some Drugs of Abuse)
1. **Opioid overdose** presents with **bradycardia**, **hypothermia**, **hypotension**, **decreased respiration rate**, and **miosis** and is treated with **naloxone**.
2. **Benzodiazepine overdose** causes **central nervous system depression** with typically **normal vital signs and eye examination**; **flumazenil** is **not generally recommended** because reversal **may precipitate seizures**.
3. **Sympathomimetic toxicity** is characterized by **tachycardia**, **hypertension**, **fever**, **diaphoresis**, **mydriasis**, **agitation**, and **seizure** with laboratory findings of **elevated creatine kinase**, **elevated liver chemistries**, and **elevated creatinine**; **benzodiazepines** are **firstâ€‘line** for agitation, **Î²â€‘blockers should be avoided**, and **haloperidol may worsen hyperthermia**.
4. **Cocaine** toxicity prominently features **myocardial infarction** with a typical duration of **~30 minutes**.
5. **Methamphetamine** toxicity often features **violent agitation** and **hyponatremia** with a typical duration of **~20 hours**.
6. **MDMA (3,4â€‘methylenedioxymethamphetamine) toxicity** is associated with **hyponatremia** and **serotonin syndrome**.
7. **Bath salt (â€œplant foodâ€) ingestion** can cause **hallucinations** and **violent agitation** lasting **up to 48 hours** and may have a **negative urine drug screen**.
8. **Dextromethorphan** overdose may cause **tachycardia**, **hypertension**, **agitation**, and **coma**.
9. **Lysergic acid diethylamide (LSD)** overdose may cause **mild tachycardia** and **hypertension** with **rare fever or hemodynamic instability**; **benzodiazepines** are **first line** for agitation.
10. **Phencyclidine (PCP)** toxicity produces **variable mental status** changes, including **increased agitation**, **central nervous system depression**, and **nystagmus**.
11. **Synthetic cannabinoid (â€œSpice,â€ â€œKâ€‘2â€) exposure** is associated with **tachycardia**, **greater agitation** than marijuana, **elevated creatinine**, and a **negative urine drug screen**.
